What were Metropolis Healthcare Ltd's latest quarterly results?
Metropolis Healthcare Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +75.9% (stable)
- Revenue Growth YoY: +23.2%
- Operating Margin: 25.0% (volatile)
Metropolis Healthcare Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +16.2%Average6w Streak
In , Metropolis Healthcare Ltd (Diagnostics) is outperforming Nifty 500 with +16.2% relative strength. Fundamentals: Average. On a 6-week streak.
Metropolis Healthcare Ltd Key Facts
- PE Ratio
- 57.4x
- Market Cap
- ₹11,265 Cr
- PAT Growth YoY
- +76%
- Revenue Growth YoY
- +23%
- OPM
- 25.0%
- RS vs Nifty 500
- +16.2%
PE: Mid ExpansionEmerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
💪Debt reduced 13% YoY — balance sheet strengthening
👔Promoter stake down 0.5% this quarter
🌐FII stake decreased 6.0% this quarter
🏛️DII accumulation — stake up 5.1%
💰Trading 49% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+76%
Stable
Revenue YoY
+23%
Stable
Operating Margin
25.0%
+700 bps YoY
PE Ratio
57.4
Current Price
₹543
Dividend Yield
0.37%
Fundamental Score
58/100
Average
3Y PAT CAGR
+10%
Market Cap
11.3K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Metropolis Healthcare Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +23% | +13% | Stable |
| PAT (Net Profit) | +76% | +10% | Stable |
| OPM | 25.0% | +700 bps | Volatile |
Other Top Diagnostics Stocks Beating Nifty 500
Frequently Asked Questions: Metropolis Healthcare Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Metropolis Healthcare Ltd's profit growing or declining?
Metropolis Healthcare Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +75.9% (latest quarter)
- PAT Growth QoQ: +21.4% (sequential)
- 3-Year PAT CAGR: +10.1%
- Trend: Stable — consistent growth pattern
What is Metropolis Healthcare Ltd's revenue growth trend?
Metropolis Healthcare Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +23.2%
- Revenue Growth QoQ: +4.7% (sequential)
- 3-Year Revenue CAGR: +12.8%
How is Metropolis Healthcare Ltd's operating margin trending?
Metropolis Healthcare Ltd's operating margin is volatile.
- Current OPM: 25.0%
- OPM Change YoY: +7.0% basis points
- OPM Change QoQ: +2.0% basis points
What is Metropolis Healthcare Ltd's 3-year profit and revenue CAGR?
Metropolis Healthcare Ltd's long-term compounding rates
- 3-Year Profit CAGR: +10.1%
- 3-Year Revenue CAGR: +12.8%
Is Metropolis Healthcare Ltd's growth accelerating or decelerating?
Metropolis Healthcare Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +40.4% bps
- Sequential Acceleration: +42.2% bps
What is Metropolis Healthcare Ltd's trailing twelve month (TTM) performance?
Metropolis Healthcare Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹191 Cr
- TTM PAT Growth: +31.7% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +23.7% YoY
- TTM Operating Margin: 24.0%
Is Metropolis Healthcare Ltd overvalued or undervalued?
Metropolis Healthcare Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 57.4x
- Price-to-Book: 7.4x
What is Metropolis Healthcare Ltd's current PE ratio?
Metropolis Healthcare Ltd's current PE ratio is 57.4x.
- Current PE: 57.4x
- Market Cap: 11.3K Cr
- Dividend Yield: 0.37%
How does Metropolis Healthcare Ltd's valuation compare to its history?
Metropolis Healthcare Ltd's current PE is 57.4x.
- Current PE: 57.4x
- Valuation Assessment: Significantly Overvalued
What is Metropolis Healthcare Ltd's price-to-book ratio?
Metropolis Healthcare Ltd's price-to-book ratio is 7.4x.
- Price-to-Book (P/B): 7.4x
- Book Value per Share: ₹73
- Current Price: ₹543
Is Metropolis Healthcare Ltd a fundamentally strong company?
Metropolis Healthcare Ltd is rated Average with a fundamental score of 58.41/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +23.2% (10% weight)
- PAT Growth YoY: +75.9% (10% weight)
- PAT Growth QoQ: +21.4% (10% weight)
- Margins stable (10% weight)
Is Metropolis Healthcare Ltd debt free?
Metropolis Healthcare Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹232 Cr
What is Metropolis Healthcare Ltd's return on equity (ROE) and ROCE?
Metropolis Healthcare Ltd's return ratios over recent years
- FY2024: ROCE 16.0%
- FY2025: ROCE 15.0%
- FY2026: ROCE 18.0%
Is Metropolis Healthcare Ltd's cash flow positive?
Metropolis Healthcare Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹351 Cr
- Free Cash Flow (FCF): ₹128 Cr
- CFO/PAT Ratio: 184% (strong cash conversion)
What is Metropolis Healthcare Ltd's dividend yield?
Metropolis Healthcare Ltd's current dividend yield is 0.37%.
- Dividend Yield: 0.37%
- Current Price: ₹543
Who holds Metropolis Healthcare Ltd shares — promoters, FII, DII?
Metropolis Healthcare Ltd's shareholding pattern (Mar 2026)
- Promoters: 48.9%
- FII (Foreign): 10.4%
- DII (Domestic): 35.8%
- Public: 4.9%
Is promoter holding increasing or decreasing in Metropolis Healthcare Ltd?
Metropolis Healthcare Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 48.9% (Mar 2026)
- Previous Quarter: 48.9% (Dec 2025)
- Change: -0.01% (decreasing — worth monitoring)
How long has Metropolis Healthcare Ltd been outperforming Nifty 500?
Metropolis Healthcare Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Is Metropolis Healthcare Ltd a new momentum entry or an established outperformer?
Metropolis Healthcare Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
Is Metropolis Healthcare Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Metropolis Healthcare Ltd may be worth studying
- Earnings growing at +75.9% YoY
- Cash flow is positive — CFO ₹351 Cr
What is the investment thesis for Metropolis Healthcare Ltd?
Metropolis Healthcare Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +23.2% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Metropolis Healthcare Ltd?
Metropolis Healthcare Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.